Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaBaMet: Cabazitaxel for Brain Metastases in Breast or Lung Cancer
2013-005545-37Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Dec 2014
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in breast cancer, bronchial carcinoma and brain metastases, sponsored by AIO-Studien. Primary endpoint: Objective tumor response of brain metastases. Started Dec 2014; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
breast cancerbronchial carcinomabrain metastases
Beyond the preview
Go deeper on 2013-005545-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005545-37.